Navigation Links
Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C
Date:11/2/2009

virus at week 12 of narlaprevir treatment compared to 17 percent of patients at week 12 in the control arm.

Narlaprevir is a next-generation oral HCV protease inhibitor that achieves once-daily dosing through the use of low-dose ritonavir as a metabolic inhibitor. The NEXT-1 study evaluates 12 weeks of narlaprevir 200 mg or 400 mg once-daily or 100 mg twice daily with low-dose ritonavir (100 mg) in combination with PEGINTRON (1.5 mcg/kg once weekly) and REBETOL (600-1400 mg daily), followed by PEGINTRON and REBETOL alone for an additional 12 or 36 weeks (24 or 48 weeks total). The study includes two treatment arms in which patients receive a 4-week lead-in of PEGINTRON and REBETOL prior to receiving narlaprevir 200 mg or 400 mg once-daily in the above regimen. All patients in the narlaprevir arms have completed narlaprevir dosing. The control arm is PEGINTRON and REBETOL alone for 48 weeks.

In this study, the rate of adverse events in the narlaprevir arms was similar to that in the peginterferon and ribavirin control arm, except for an increase in anemia (there were no discontinuations due to anemia) and an increase in low neutrophil counts (with no clinical sequelae). The most frequently seen adverse events up through 12 weeks of treatment were fatigue, nausea, flu-like illness, headache and insomnia. No increase in skin adverse events (rash or pruritus) beyond what was seen in the peginterferon and ribavirin control was observed.

For more information about ongoing narlaprevir clinical studies, please visit www.clinicaltrials.gov.

About Hepatitis C

Hepatitis C is a serious and potentially life-threatening disease. It is the most common blood-borne infection in America and Europe, and the most common form of liver disease, affecting nearly 5 million people in the United States, 5 million in Europe and some 200 million people worldwide. It is the lead
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
2. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
3. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
4. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
5. Schering-Plough Reports Top-Line Results of the IDEAL Study
6. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
7. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
8. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
9. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
10. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
11. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/hcb7bz/pharmaceutical ) has announced the addition ... November 16-18, 2015)" conference to their offering. Regulatory requirements ... Columbia, Peru , Brazil , ... , Paraguay , Venezuela , ... Chile This seminar can be viewed both ...
(Date:9/2/2015)... NEW YORK , Sept. 2, 2015  Seeger ... knee implant bellwether trial will commence October 13, 2015. ... 1995 using the 510K fast-track approval program, Zimmer NexGen ... The program only requires that companies provide evidence that ... approved product in order to gain permissions. ...
(Date:9/2/2015)... DUBLIN , Sept. 2, 2015 ... the addition of the "Medical Device Studies: ... conference to their offering. ... who are involved in gathering clinical evidence required ... data is required for all medical devices and ...
Breaking Medicine Technology:Pharmaceutical Regulatory Affairs in Latin America Seminar - London, UK - November 16-18, 2015 2Seeger Weiss LLP Reports That Zimmer NexGen Knee MDL Bellwether Trial Date Set For October 13, 2015 2Medical Device Studies: Clinical Evidence Course - London, UK - November 10-11, 2015 2
... -- ADVANCE FOR RELEASE AT 5 P.M. EST MONDAY, ... Patients,who undergo complete prostate removal are less likely to ... done by an,experienced surgeon in a hospital that does ... the Agency for Healthcare Research and,Quality, part of the ...
... Regions of Body Consistent with Overall PASI ... Response in REMICADE-Treated Patients, SAN ANTONIO, ... placebo-controlled trials showed patients with moderate,to severe plaque psoriasis receiving ... each of the four body regions,(head, trunk, lower and upper ...
Cached Medicine Technology:Outcomes Vary for Prostate Cancer Patients Choosing Surgery; Overall, No Treatment Proven Superior 2Outcomes Vary for Prostate Cancer Patients Choosing Surgery; Overall, No Treatment Proven Superior 3Outcomes Vary for Prostate Cancer Patients Choosing Surgery; Overall, No Treatment Proven Superior 4REMICADE-Treated Patients Experienced Rapid and Substantial Improvement in Psoriasis in Critical Regions of Body 2REMICADE-Treated Patients Experienced Rapid and Substantial Improvement in Psoriasis in Critical Regions of Body 3REMICADE-Treated Patients Experienced Rapid and Substantial Improvement in Psoriasis in Critical Regions of Body 4REMICADE-Treated Patients Experienced Rapid and Substantial Improvement in Psoriasis in Critical Regions of Body 5REMICADE-Treated Patients Experienced Rapid and Substantial Improvement in Psoriasis in Critical Regions of Body 6REMICADE-Treated Patients Experienced Rapid and Substantial Improvement in Psoriasis in Critical Regions of Body 7REMICADE-Treated Patients Experienced Rapid and Substantial Improvement in Psoriasis in Critical Regions of Body 8REMICADE-Treated Patients Experienced Rapid and Substantial Improvement in Psoriasis in Critical Regions of Body 9REMICADE-Treated Patients Experienced Rapid and Substantial Improvement in Psoriasis in Critical Regions of Body 10
(Date:9/2/2015)... KY (PRWEB) , ... September 02, 2015 , ... Ericson ... the CDI Education Director for HCPro and Associate Director of Education for the Association ... CDI, Advancing CDI and ICD-10 for CDI Boot Camps. She serves as a CDI ...
(Date:9/2/2015)... ... September 02, 2015 , ... The 2015 China Overseas ... investment and business conference will be hosted at five star Beijing Kunlun Hotel ... networking conference will feature leading EB-5 industry professionals and Chinese private equity partners ...
(Date:9/2/2015)... Minneapolis, MN (PRWEB) , ... September 02, 2015 ... ... is commercializing products for the upper extremity surgical market, announced today that more ... instrument for trigger releases in the hand. Plus, nearly 70 of these ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... On September ... to attend doTERRA’s annual convention, the largest single-company convention to date for the state ... and look forward to a tremendous event,” states David Stirling, doTERRA CEO. “One of ...
(Date:9/2/2015)... ... September 02, 2015 , ... The payroll conference ... days of payroll education covering legislative updates, including unemployment, global payroll best practices, ... representatives from Ceridian, Ultimate Software, the American Payroll Association, Barnett Associates, and the ...
Breaking Medicine News(10 mins):Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 2Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 3Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 4Health News:The 2015 China Overseas Investment and Entrepreneurship Summit (COIES) Announced 2Health News:Trigger Tome Surpasses 600 Successful Patient Procedures 2Health News:doTERRA to Host the Largest Single-Company Convention in the State of Utah 2Health News:23rd Annual NJ Statewide Payroll Conference in Vernon, NJ at the Minerals Hotel on October 15-16, 2015 2
... indeed a ‘ubiquitous’ festival, as it is celebrated throughout the ... 26 million Indian homes.// The joys of the season is ... making the most of the special bargains and discounts of ... the celebration. Plans are afoot in great enthusiasm as homes ...
... The surprising structure and properties of a protein responsible for ... it binds its target RNA// -- are described by researchers ... is an essential nutrient, and defects in uptake and metabolism ... a variety of diseases and disorders, including heart disease, arthritis ...
... Agricultural Research Service (ARS) funded research suggest that berry extracts ... found that laboratory animals, which were fed berry extracts and ... damage to brain function. ,Three groups ... for about three months. The control group was fed a ...
... Health plans, school girls as young as 12 could ... cause cervical cancer//. Researchers have found that the Human ... of cervical cancer, which kills around 1,000 women a ... the human papilloma virus (HPV) before they become sexually ...
... (AL) on Saturday voiced concern on the developments regarding the ... Libyan children with the HIV/AIDS virus//. AL also issued an ... ,The AL also expressed full sympathy underlining the ... order to curb the consequences of this "painful human catastrophe". ...
... (FDA) is expected to announce soon the results of its ... some species of cloned animals. ,Two experts ... Agriculture Policy are available to media to comment on the ... safety of consuming meat and milk from cloned animals. ...
Cached Medicine News:Health News:Come Apart and Rest Awhile – It’s Christma 2Health News:Come Apart and Rest Awhile – It’s Christma 3Health News:Structure of Iron Regulatory Protein-RNA Complex Solved 2
... Vascular Graft, the newest vascular graft offering ... leader in vascular surgical products for more ... reducing kinking and compression problems that ... graft provides all of the benefits of ...
... rasping necessary in cruciate ligament reconstruction procedures ... bone surface. This condition, if not rectified ... cruciate replacement. The GORE SMOOTHER Crucial Tool ... procedures. The tool functions as both a ...
Vikingselect™ Intra-Operative Monitoring (IOM)....
... system has been designed by practicing ... of the ever changing and demanding ... analyzing data from multiple modalities, including: ... and multiple patients at multiple sites. ...
Medicine Products: